Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-...
Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms
About this item
Full title
Author / Creator
Publisher
United States: Mary Ann Liebert, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Mary Ann Liebert, Inc
Subjects
More information
Scope and Contents
Contents
Vascular endothelial growth factor-A (VEGF-A) is one of the most important factors inducing angiogenesis in tumors. Nine splice-variant isoforms of VEGF-A have been identified, each having different properties. Recently, we showed that radiolabeled anti-VEGF monoclonal antibody, bevacizumab, accumulates specifically in VEGF-A expressing tumors. In...
Alternative Titles
Full title
Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67195996
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67195996
Other Identifiers
ISSN
1084-9785
E-ISSN
1557-8852
DOI
10.1089/cbr.2008.0574
